A case of cancer‐associated myositis with anti‐Mi‐2 antibody: False‐positive anti‐transcriptional intermediary factor 1‐γ antibody by commercial enzyme‐linked immunosorbent assay

Nawata, Takashi; Kubo, Makoto; Oishi, Keiji; Murata, Yoriyuki; Oishi, Mariko; Okazaki, Yuka; Omoto, Masatoshi; Okazaki, Yoshikazu; Kanda, Takashi; Kuwana, Masataka; Yano, Masafumi

doi:10.1111/1756-185x.13449

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent across studies evaluating assay performance [24,27]. Anti-TIF1g is highly associated with malignancy in adult patients, and as such is a key biomarker for cancer diagnosis Conversely, recent investigations indicate that crossreactivity with anti-Mi2 will result in an increased rate of anti-TIF1g false positive results [34].…”

Section: Recent Advances In Myositis-specific Autoantibody Assayssupporting

confidence: 69%

Myositis autoantibodies: recent perspectives

Riddell¹,

Bagby²,

McHugh

2020

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewTo provide an overview of recent discoveries related to myositis-specific autoantibodies (MSAs) and assays used for their measurement. Recent findingsNew autoantibody specificities have been reported including a MSA directed against eukaryotic initiation factor 3 and a myositis-associated autoantibody directed against heat shock factor 1. The association of anti-TIF1g with cancer-associated dermatomyositis dependent on age has been confirmed in several large cohorts. Despite MSAs being almost entirely mutually exclusive, several myositis autoantigens are overexpressed in regenerating muscle and do not correlate with the corresponding MSA in any one patient. Further mechanisms may determine the final MSA specificity and are likely to include the need for autoantigen processing and presentation with adaptive T-cell help. The presence of CD4-positive T cells specific for histidyl tRNA synthetase protein in bronchial lavage fluid from antisynthetase patients lends support to this view. Finally, it is widely held that MSA do play an important role in clinical practice among some evidence and concern about commercial assay reliability.

show abstract

Section: Recent Advances In Myositis-specific Autoantibody Assayssupporting

confidence: 69%

Myositis autoantibodies: recent perspectives

Riddell¹,

Bagby²,

McHugh

2020

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Anti-Mi-2 antibody-positive lung cancer-associated polymyositis

et al. 2023

View full text Add to dashboard Cite

A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting

Kuwana

Okazaki

2022

Modern Rheumatology

View full text Add to dashboard Cite

Objective To develop a multianalyte assay for the detection of dermatomyositis (DM)-related autoantibodies using immunoprecipitation (IP) combined with immunoblotting (IB). Methods Sera from 116 DM patients were subjected to RNA and protein immunoprecipitation assays as well as commercial enzyme-linked immunosorbent assays (ELISAs) for anti-aminoacyl tRNA synthetase, anti-melanoma differentiation antigen 5 (MDA5), anti-Mi-2, anti-transcriptional intermediary factor-1γ (TIF-1γ), and anti-U1 ribonucleoprotein antibodies. The IP/IB assay was developed by immunoprecipitation of autoantigens from HeLa cell extracts using patient sera, followed by immunoblotting with an antibody against Mi-2, TIF-1γ, OJ, nuclear matrix protein (NXP)-2, MDA5, PM/Scl, small ubiquitin-like modifier activating enzyme (SAE), or Ku. A multianalyte assay was designed by mixing primary antibodies in the IP/IB assay. Results IP assays identified any DM-related autoantibodies in 100 patients (86%), of which 82% were covered by commercial ELISAs, with a false-positive result in two sera and a false-negative result in one. The results obtained from the multianalyte IP/IB assay and ‘gold-standard’ IP assays were concordant in terms of the presence or absence of anti-MDA5, anti-TIF-1γ, anti-OJ, anti-NXP-2, anti-PM/Scl, anti-SAE, anti-Mi-2, and anti-Ku antibodies. Conclusion This multianalyte IP/IB assay combined with commercial ELISAs is an alternative to ‘gold-standard’ IP assays for the detection of DM-related autoantibodies.

show abstract

A case of cancer‐associated myositis with anti‐Mi‐2 antibody: False‐positive anti‐transcriptional intermediary factor 1‐γ antibody by commercial enzyme‐linked immunosorbent assay

Abstract: KEYWORDS: anti-Mi-2 antibody, anti-transcriptional intermediary factor 1-γ antibody, dermatomyositis, enzyme-linked immunosorbent assay, false positive

Cited by 3 publications

References 17 publications

Myositis autoantibodies: recent perspectives

Myositis autoantibodies: recent perspectives

Anti-Mi-2 antibody-positive lung cancer-associated polymyositis

A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting

Contact Info

Product

Resources

About